Selected data models

You must log in to select data models for download or further analysis.

21 Search results.
Relevance Rating New first Old first

New Onset Diabetes Mellitus GSK study Chronic Coronary Heart Disease NCT00799903

- 1/1/18 - 1 form, 6 itemgroups, 18 items, 1 language
Itemgroups: Diabetes Mellitus Date of diagnosis, Diagnosis based on fasting plasma glucose, Diagnosis based on casual plasma glucose, Diagnosis based on oral glucose tolerance test, New anti-diabetic medication, HbA1c
Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: New Onset Diabetes Mellitus

Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization

- 9/13/16 - 1 form, 4 itemgroups, 51 items, 1 language
Itemgroups: Comorbidity, risk factor Thrombosis, Ultrasonography, registration; Randomization
Study documentation part: Baseline study (T0) – Risk Factors / Sonography in angiology / Randomization, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Study end / Study dropout VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Study end / Study dropout

- 9/20/21 - 1 form, 3 itemgroups, 17 items, 1 language
Itemgroups: study end, Indication study termination, measures study termination
Study documentation part: Study end / Study dropout, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Baseline study (T0) – Informed Consent and Inclusion criteria VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Baseline study (T0) – Informed Consent and Inclusion criteria

- 9/20/21 - 1 form, 3 itemgroups, 52 items, 1 language
Itemgroups: Informed Consent, Inclusion Criteria, Exclusion Criteria
Study documentation part: Baseline study (T0) – Informed Consent and Inclusion criteria, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Other diseases and therapies except tumors VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Other diseases and therapies except tumors

- 3/15/21 - 1 form, 1 itemgroup, 9 items, 1 language
Itemgroup: other disease; treatment
Study documentation part: Other diseases and therapies except tumors, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

MRT SHIP-Trend-0 MRT-findings: angio

- 12/12/17 - 1 form, 1 itemgroup, 155 items, 2 languages
Itemgroup: MRT-findings: angio
MRT-findings: angio form of SHIP Study (Study of Health in Pomerania), conducted by the University of Greifswald. SHIP unique domain name SHIP.SHIPTrend0.MRT.MRTBEF.MRTANG. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html.
 Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

End form: Enoxaparin administration measures for the intervention group VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Enoxaparin administration measures for the intervention group

- 9/28/16 - 1 form, 3 itemgroups, 52 items, 1 language
Itemgroups: Drug administration Enoxaparin, Therapy interrupted, prescription Heparin
Study documentation part: Enoxaparin administration measures for the intervention group, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Investigation between T0 and T1 – Platelet checks for intervention group VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Investigation between T0 and T1 – Platelet checks for intervention group

- 9/28/16 - 1 form, 1 itemgroup, 37 items, 1 language
Itemgroup: measures Intervention Group
Study documentation part: Investigation between T0 and T1 – Platelet checks for intervention group, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Thrombosis / pulmonary embolism VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Thrombosis / pulmonary embolism

- 9/22/16 - 1 form, 3 itemgroups, 31 items, 1 language
Itemgroups: Thrombosis; Pulmonary Embolism, Vascular Medicine, outcome
Study documentation part: Thrombosis / pulmonary embolism, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Adverse events VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - Adverse events

- 9/21/16 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Adverse Events
Study documentation part: Adverse events, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Port / CVC VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - End form: Port / CVC

- 9/14/16 - 1 form, 1 itemgroup, 8 items, 1 language
Itemgroup: Port Catheters; Central venous catheter
Study documentation part: End form: Port / CVC, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

End form: Chemotherapy VTETumor02 Prophylactic Treatment of Thromboembolism with Enoxaparin EudraCT number: 2007-002036-28 - End form: Chemotherapy

- 9/14/16 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: Chemotherapy
Study documentation part: End form: Chemotherapy, VTETumor02. This is a prospective, randomized, controlled, unicentric, open study on prophylactic treatment of thromboembolism with Enoxaparin in non-surgical oncology patients under systemic antineoplastic therapy. Principal Investigator Prof. Dr. Max E. Scheulen, Clinic and Polyclinic for Internal medicine (Tumor research), University Hospital of Essen, Germany. EudraCT number: 2007-002036-28, Version 0.6 vom 06.08.09.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial